AESYRA
13.12.2023 07:32:27 CET | Business Wire | Press release
Aesyra, a medical device company pioneering oral appliance technologies to improve sleep, today announced it has raised $3 million in seed financing. The round was led by Supermoon Capital (USA), the world’s first fund focused on sleeptech, and deep tech investor Creadd Ventures (Switzerland) with participation from existing investor Zürcher Kantonalbank.
The new financing will support the development and commercialization of Aesyra’s AesyBite® line of products for accurate monitoring and treatment of sleep bruxism and sleep apnea. Sleep bruxism is a sleep disorder often linked to sleep apnea, which affects nearly a billion people worldwide. A spin-off of the Federal Institute of Technology of Lausanne (EPFL) in Switzerland, Aesyra has pioneered a powerful technology system — that combines a unique oral appliance device, proprietary sensors, and AI — that has demonstrated over 70% reduction of bruxism activity for users. Powering Aesyra’s AesyBite™ are technology developed by EPFL researchers and algorithms that leverage over 10 years of sleep research data.
"This significant investment marks a pivotal moment for Aesyra,” said Marco Letizia, founder and CEO of Aesyra. “We are thrilled to partner with Supermoon Capital and Creadd Ventures, who share our vision of driving meaningful change within the sleep industry. With their support, we are well-positioned to accelerate the deployment of our groundbreaking solutions, ultimately improving patient outcomes and advancing healthcare practices."
"Aesyra’s advanced technology is a tremendous breakthrough in the field of sleep science for the treatment of sleep bruxism and sleep apnea,” said Michael Masterson, Managing Partner at Supermoon Capital “We are impressed by the company’s unique approach, strong leadership team and unwavering commitment to revolutionize healthcare, and we are looking forward to working closely with Aesyra to support its mission.”
"We selected Aesyra as the first investment of Creadd Ventures since it perfectly fits our philosophy to invest in companies that have the potential to make a profound impact on the quality of life of patients,” said Lorenzo Leoni, Founder and Managing Partner at Creadd Ventures.
Masterson Leoni will join the Board of Directors of Aesyra, bringing their extensive industry expertise and strategic guidance to accelerate the company's growth and success.
About Aesyra:
Aesyra is a privately held, clinical-stage company dedicated to develop, manufacture and commercialize smart medical devices able to accurately monitor and relieve sleep bruxism and sleep apnea. The company has developed a line of devices (AesyBite®) using innovative and proprietary sensors and algorithms that allows intraoral measurements of several factors during sleep and is capable to actively reduce bruxism and improve patients’ quality of life. For more information, please visit www.aesyra.com.
About Supermoon Capital:
Supermoon Capital is the only venture capital firm in the world focused exclusively on the sleep technology market. The San Francisco-based firm partners with visionary innovators across the sleep market spectrum encompassing chronobiology, neurotech, biotech, pharmaceuticals, medtech, consumer interventions, and enterprise solutions. Supermoon and its global network of prominent academics, strategic partners, and renowned sleep scientists support companies across a range of functions, including product development, go-to-market strategy, and growth financing. For more information, please visit www.supermooncapital.com.
About Creadd Ventures:
Creadd Ventures is a new venture capital fund with a focus on investing Biomedical, DeepTech and SAAS companies based in Switzerland and Europe. The fund’s investment strategy involves targeting emerging early-stage companies with strong management teams, a solid and proprietary scientific foundation, and a clear go to market strategy. Creadd leverages the extensive experience and network of both founding partners as entrepreneurs and fund managers. For more information, please visit www.creadd.ch.
About Zürcher Kantonalbank
Zürcher Kantonalbank is an independent public-law institution of the Canton of Zurich, incorporated under the laws of the Canton of Zürich. Its registered corporate domicile and principal place of business is in Zurich, Switzerland. It has received top ratings from the rating agencies Standard & Poor’s, Moody’s and Fitch (AAA/Aaa). With more than 6,000 employees across the group, the bank’s core activities include financing businesses, asset and wealth management, trading, capital market transactions, deposits, payment transactions and card business. www.zkb.ch
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231212403553/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers17.7.2026 19:10:00 CEST | Press release
Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolioBoth INCB161734, an investigational, potent, selective and orally bioavailable KRAS G12D inhibitor, and INCA338901, a TGFβR2×PD-1 bispecific antibody, are being evaluated in ongoing Phase 3 programs as first-line treatments for patients with advanced pancreatic ductal adenocarcinoma (PDAC) and microsatellite stable (MSS) colorectal cancer, respectively Incyte (Nasdaq:INCY) today announced that it will highlight data from several programs in its oncology portfolio in six presentations at the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid. “The data at ESMO will further illustrate Incyte’s commitment to advancing innovation for patients with cancer,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Among the presentations are important updates from our KRAS G12D inhibitor in advanced pancreatic ca
STL Expands Its Optical Connectivity Portfolio in the US with the CONCAT Solution17.7.2026 14:24:00 CEST | Press release
STL Optical Connectivity NA, LLC, (STLOC), a U.S. subsidiary of STL (Sterlite Technologies Ltd.) [NSE: STLTECH], a leading connectivity solutions provider for AI-ready digital infrastructure, today announced that it launched its new advanced FTTH solution, CONCAT, after successfully completing field trials on the networks of one of the largest telecom service providers in the United States. Following successful field validation, CONCAT is now available to digital infrastructure providers seeking faster fiber rollouts with reduced deployment complexity and labor. It enables up to 71% in labor cost savings by eliminating most field splicing through factory-assembled, pre-connectorized fiber segments that deliver plug-and-play installation. CONCAT simplifies fiber deployment by shifting critical fiber preparation and termination into a controlled manufacturing environment ensuring consistent quality, faster installation, and lower operational risk in the field. CONCAT solution is ideal fo
Aqemia and Sanofi Expand Their Research Collaboration17.7.2026 12:30:00 CEST | Press release
A new target nomination and a milestone payment mark the next step of the multi-year partnership first announced in December 2023 Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the global pharmaceutical company, Sanofi. The expansion is marked by the nomination of a new therapeutic target and an additional payment. The collaboration, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and milestone payments across programs. It spans the drug discovery journey from the identification of the very first hits to the selection of a development candidate. Aqemia leverages Qemi, its proprietary physics-based generative AI platform, to design novel molecules addressing Sanofi’s targets of choice, working in close collaboration with Sanofi scientific teams. Sanofi leads wet lab research, devel
China's ~$900B Live-Commerce Market Now Approaches US E-Commerce Scale17.7.2026 12:30:00 CEST | Press release
The consumer habits reshaping global retail were built in the East — and most Western shoppers haven't yet adopted them. NIQ report shows that brands still treating live, social, and quick commerce as "emerging" risk being left behind. The center of gravity in global retail has shifted East. The formats now driving the fastest growth in global retail (live shopping, social commerce, and delivery in minutes) were pioneered and scaled in Asia, and most Western consumers have yet to adopt them. According to NIQ (NYSE: NIQ), a leading consumer intelligence company, in its global report The Commerce Revolution: Where East Meets West, the gap between East and West is still vast. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717253489/en/ China´s USD 900bn live shopping boom now approaches the scale of the US E-commerce The scale is already substantial. China's live-commerce market alone was worth roughly $900 billion in 2025,
Ant International’s Alipay+ Connects Argentina's National QR Payment Scheme via PVS,Enabling for Cross-Border Digital Payment Nationwide at Millions of Merchants17.7.2026 12:17:00 CEST | Press release
Alipay+, a global digital payment gateway under Ant International, today announced that it will enable global travellers to make QR code payments at millions of merchants across Argentina through integration with the country's national QR payment scheme Transferencias 3.0, in partnership with PVS, a fintech company specialized in developing customized payment solutions in Latin America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717276406/en/ By connecting to Argentina's national QR payment scheme, Alipay+ now enables global travellers in the country to make convenient QR code payments at merchants nationwide. This service helps to enhance global travellers' travel experiences in Argentina, allowing them to pay seamlessly at restaurants, malls and tourist attractions. Using an Alipay+ partner payment app, they can now scan the national QR code displayed at all merchants to make cross-border payments across Argentina,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
